Search this website Home Company Products News & Releases Careers Contact Us Transplantation Is Our Life’s Work Veloxis is a specialty pharmaceutical company committed to helping patients realize the full possibilities of life after transplant. Our sole focus is to develop innovative therapies and programs that provide meaningful support for transplant healthcare providers and the patients they treat. PRODUCTS Veloxis is dedicated to improving patient care through innovative therapies. LEARN MORE TRANSPLANT SUPPORT Veloxis is committed to patient access and financial support for kidney transplant patients. LEARN MORE INVESTOR RELATIONS Veloxis Pharmaceuticals, Inc. is a wholly owned subsidiary of Asahi Kasei Corporation. LEARN MORE ©2021 All rights reserved. Veloxis Pharmaceuticals, Inc. US-UNB-2100005 7/21 Info@veloxis.com | 1-844-VELOXIS (835-6947), Monday-Friday, 9AM-7PM ET Sitemap | Contact | Privacy Policy | Disclaimer We'll assume you're ok with this, but you can opt-out if you wish. Cookie settingsACCEPT

Skip to main navigation Skip to primary sidebar BACK TO THE CORPORATE SITE INVESTOR RELATIONS IR Menu News & Releases Download Center Corporate Governance Financial Information General Meetings INVESTORS Latest News & Releases June 22, 2020 Transplant Therapeutics Consortium Receives Acceptance of Letter-of-Intent for iBox Scoring System as a Reasonably Likely Surrogate Endpoint from the Biomarker Qualification Program READ MORE February 17, 2020 Extraordinary General Meeting of Veloxis Pharmaceuticals A/S, 17 February 2020 READ MORE January 29, 2020 Nasdaq Copenhagen A/S has Accepted Veloxis Pharmaceuticals A/S' Request for Delisting of its Shares from Nasdaq Copenhagen A/S READ MORE © 2021 All rights reserved. Veloxis Pharmaceuticals Inc. ENV-18-090.0 06/18 info@veloxis.com | 1-844-VELOXIS (835-6947), Monday-Friday, 9AM-7PM ET Sitemap | Contact | Privacy Policy | Disclaimer